CDER RESPONDS TO MANAGEMENT OF LACK OF AVAILABILITY OF FINISHED DRUG PRODUCT OR API Recently the FDA has added a new standardized paragraph to each of its Warning Letters for both Finished Drug Products and for Active Pharmaceutical Ingredients.  Please review how the FDA desires you to respond. "If, as a result of receiving this Warning Letter or in general, you … [Read more...]